Trial Title:
Pembro Plus CAR T-cell Therapy in R/R in PMBCL
NCT ID:
NCT05934448
Condition:
Primary Mediastinal Large B-cell Lymphoma (PMBCL)
Primary Mediastinal Large B Cell Lymphoma
Primary Mediastinal Large B-Cell Lymphoma Refractory
Primary Mediastinal Large B-Cell Lymphoma Recurrent
Epstein-Barr Virus Positive Diffuse Large B-Cell Lymphoma
T-Cell/Histiocyte-Rich Large B-Cell Lymphoma
Conditions: Official terms:
Epstein-Barr Virus Infections
Lymphoma
Lymphoma, B-Cell
Lymphoma, Large B-Cell, Diffuse
Cyclophosphamide
Pembrolizumab
Fludarabine
Conditions: Keywords:
Primary Mediastinal Large B-cell Lymphoma (PMBCL)
Primary Mediastinal Large B Cell Lymphoma
Primary Mediastinal Large B-Cell Lymphoma Refractory
Primary Mediastinal Large B-Cell Lymphoma Recurrent
T-Cell/Histiocyte-Rich Large B-Cell Lymphoma
Epstein-Barr virus-positive diffuse large B-cell lymphoma
Study type:
Interventional
Study phase:
Phase 2
Overall status:
Recruiting
Study design:
Allocation:
N/A
Intervention model:
Single Group Assignment
Primary purpose:
Treatment
Masking:
None (Open Label)
Intervention:
Intervention type:
Drug
Intervention name:
Pembrolizumab
Description:
Pembrolizumab via iv, dosage and timing per protocol
Arm group label:
PEMBROLIZUMAB
Other name:
Keytruda
Intervention type:
Drug
Intervention name:
Lymphodepletion Chemotherapy
Description:
Participants will undergo lymphodepleting chemotherapy (fludarabine, cyclophosphamide)
for CAR T-cell therapy as per SOC
Arm group label:
PEMBROLIZUMAB
Other name:
Fludarabine
Other name:
Cyclophosphamide
Intervention type:
Drug
Intervention name:
Chimeric Antigen Receptor (CAR) Therapy Infusion
Description:
Day 0 in the hospital and will remain in the inpatient setting for observation for a
minimum of 7 days or until CAR T-cell toxicities resolve to grade 1 or better. The choice
of CAR-T product will be left to the discretion of the treating investigator.
Arm group label:
PEMBROLIZUMAB
Intervention type:
Procedure
Intervention name:
Leukapheresis
Description:
manufacturing using commercial product as per standard of care (SOC) Cycle 1 Day -21 or
earlier
Arm group label:
PEMBROLIZUMAB
Summary:
This research study is evaluating the combination of drugs, pembrolizumab with chimeric
antigen receptor (CAR) T-cell therapy, as a possible treatment for primary mediastinal
B-cell lymphoma that has recurred after prior treatment.
The names of the study drugs involved in this study are:
- Pembrolizumab
Standard treatment will include:
- CAR T-cell therapy (either axicabtagene-ciloleucel or lisocabtagene maraleucel)
- Cyclophosphamide
- Fludarabine
Detailed description:
This research study is a Phase II clinical trial. Phase II clinical trials test the
safety and effectiveness of an investigational drug to learn whether the drug works in
treating a specific disease. "Investigational" means that the drug is being studied.
The names of the study drugs involved in this study are:
- Pembrolizumab
Standard treatment will include:
- CAR T-cell therapy (either axicabtagene-ciloleucel or lisocabtagene maraleucel)
- Cyclophosphamide
- Fludarabine Participants will receive study treatment for up to 2 years and will be
followed for 5 years. It is expected that about 35 people will take part in this
research study.
The U.S. Food and Drug Administration (FDA) has approved pembrolizumab for this specific
disease after two or more lines of therapy, but not in combination with CAR T-cell
therapy.
The CAR T-cell therapies to be used in this study are axicabtagene-ciloleucel and
lisocabtagene maraleucel. The U.S. FDA has approved axicabtageneciloleucel and
lisocabtagene maraleucel as treatment options for this disease, but not in combination
with pembrolizumab.
A small subset of patients with T-cell histiocyte-rich large B-cell lymphoma and EBV+
large B-cell lymphoma will also be included.
Criteria for eligibility:
Criteria:
Inclusion Criteria:
- Histologically confirmed diagnosis of PMBCL, EBV+ DLBCL or THRLBCL at one of the
participating institutions.
- Availability of archival or freshly collected tumor tissue before study enrollment.
If archival tissue is unavailable or is determined to be inadequate, tumor tissue
must be obtained from a biopsy performed at screening, unless an exception is given
after consultation with the sponsor-investigator.
- Eligible for standard of care CAR T-cell therapy with progression after at least two
prior lines of therapy OR refractory to initial chemoimmunotherapy OR relapse within
12 months of front-line chemoimmunotherapy OR one prior line of therapy and not fit
for HSCT.
- ECOG Performance Status of 0 or 1.
- Left ventricular ejection fraction (LVEF) ≥ 50% on cardiac multiple-gated
acquisition (MUGA) scan or cardiac echocardiogram (ECHO).
- Adequate hematologic function (unless due to underlying disease, as established for
example, by extensive bone marrow involvement or due to hypersplenism secondary to
the involvement of the spleen by lymphoma per the investigator), defined as follows:
- ANC ≥ 1,000/μL
- Hemoglobin ≥ 8 g/dL
- Platelet count ≥ 50,000/μL
- Participants must have adequate organ as defined below:
- Total bilirubin ≤1.5 ×ULN OR direct bilirubin ≤ULN for participants with total
bilirubin levels >1.5 × ULN
- AST(SGOT)/ALT(SGPT) ≤2.5 × ULN (≤5 × ULN for participants with liver
involvement)
- Adequate renal function defined by serum creatinine ≤1.5 x ULN or creatinine
clearance (by Cockcroft-Gault) ≥ 40 ml/min for patients with serum creatinine
>1.5 x ULN
- At least one bi-dimensionally FDG-avid measurable lymphoma lesion on PET/CT scan,
defined as ≥ 1.5 cm in its longest dimension on CT scan, or ≥ 1 cm if extranodal
(and measurable).
- Women of childbearing potential (WOCBP) and men must agree to use effective
contraception when sexually active. This applies for the time period between signing
of the informed consent form and 6 months for WOCBP and for men after the last
administration of study treatment. A woman is considered of childbearing potential,
i.e. fertile, following menarche and until becoming post-menopausal unless
permanently sterile. Permanent sterilization methods include but are not limited to
hysterectomy, bilateral salpingectomy and bilateral oophorectomy. A postmenopausal
state is defined as no menses for continuous 12 months without an alternative
medical cause. A high follicle stimulating hormone (FSH) level in the postmenopausal
range may be used to confirm a post-menopausal state in women not using hormonal
contraception or hormonal replacement therapy. The investigator or a designated
associate is requested to advise the patient how to achieve highly effective birth
control, e.g. intrauterine device (IUD), intrauterine hormone-releasing system
(IUS), bilateral tubal occlusion, vasectomized partner, use of two forms of birth
control, and sexual abstinence. The use of condoms by male patients is required
unless the female partner is permanently sterile.
- Age ≥18 years.
- Ability to understand and the willingness to sign a written informed consent
document.
Exclusion Criteria:
- Patients in urgent need of cytoreductive therapy.
- Participants who are receiving any other investigational agents.
- History of other malignancies, except:
- Malignancy treated medically or surgically with curative intent and with no
known active disease present for ≥2 years before study registration
- Adequately treated non-melanoma skin cancer or lentigo maligna without evidence
of disease
- Adequately treated carcinoma in situ without evidence of disease.
- Localized prostate cancer and low-risk prostate cancer on active surveillance
- In the opinion of the treating investigator, there is limited potential to
interfere with the safety or efficacy of the investigational regimen. Such
exceptions must be approved by the Sponsor-Investigator.
- Has received a live vaccine within 30 days prior to study registration. Examples of
live vaccines include, but are not limited to, the following: measles, mumps,
rubella, varicella/zoster (chicken pox), yellow fever, rabies, Bacillus
Calmette-Guérin (BCG), and typhoid vaccine. Seasonal influenza vaccines for
injection are generally killed virus vaccines and are allowed; however, intranasal
influenza vaccines (eg, FluMist®) are live attenuated vaccines and are not allowed.
- Less than 6 months of response to prior PD-L1 inhibitor or PD-1 inhibitor or grade 3
or higher immune-related adverse events.
- Prior treatment with CAR T-cell therapy.
- Lactating or pregnant. Women of childbearing potential (WOCBP) must have a negative
pregnancy test (urine or serum) at screening. WOCBP will require a negative
pregnancy test within 72 hours prior to starting treatment, but eligibility for
study enrollment may be confirmed based on testing at screening.
- Known active lymphomatous involvement of the central nervous system. History of
prior CNS involvement is allowed.
- Recent infection requiring intravenous antibiotics that was completed ≤7 days before
the first dose of study drug, or any uncontrolled active systemic infection.
- Has a known history of Hepatitis B (defined as Hepatitis B surface antigen [HBsAg]
reactive) or known active Hepatitis C virus infection.
- History of Human immunodeficiency virus (HIV)-infection.
- Has received prior radiotherapy within 2 weeks of study registration. A 1-week
washout is permitted for palliative radiation (≤2 weeks of radiotherapy) to non-CNS
disease.
- Has received prior systemic anti-cancer therapy within 2 weeks or investigational
agents within 4 weeks.
- Significant liver disease, such as hepatitis (viral or non-viral) or cirrhosis
- Prior macrophage activation syndrome (MAS) or hemophagocytic lymphohistiocytosis
(HLH)
- Uncontrolled arrhythmia or Class 3 or 4 congestive heart failure as defined by the
New York Heart Association Functional Classification; or a history of myocardial
infarction, unstable angina, or acute coronary syndrome within 6 months of
enrollment.
- Known history of central nervous system or neurologic disease including stroke or
intracranial hemorrhage within 3 months prior to enrollment or seizure disorder.
Prior CNS involvement with lymphoma is allowed if previously treated with no
evidence of involvement at study entry.
- Prior solid organ or allogeneic stem cell transplant or within 6 weeks of autologous
stem cell transplant.
- Has active autoimmune disease that has required systemic treatment in the past 2
years (i.e. with use of disease modifying agents, corticosteroids or
immunosuppressive drugs).
- Is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of
prednisone equivalent) or any other form of immunosuppressive therapy within 7 days
prior to study registration. Replacement therapy (eg., thyroxine, insulin, or
physiologic corticosteroid replacement therapy for adrenal or pituitary
insufficiency, etc.) is not considered a form of systemic treatment and is allowed.
- Active pneumonitis or interstitial lung disease.
- Severe hypersensitivity (≥Grade 3) to pembrolizumab and/or any of its excipients.
- Has a history or current evidence of any condition, therapy, or laboratory
abnormality that might confound the results of the study, interfere with the
participant's participation for the full duration of the study, or is not in the
best interest of the participant to participate, in the opinion of the treating
investigator.
- Has known psychiatric or substance abuse disorders that would interfere with
cooperation with the requirements of the trial.
- Has not met requirements for standard of care CAR-T therapy
Gender:
All
Minimum age:
18 Years
Maximum age:
N/A
Healthy volunteers:
No
Locations:
Facility:
Name:
Dana-Farber Cancer Institute
Address:
City:
Boston
Zip:
02215
Country:
United States
Status:
Recruiting
Contact:
Last name:
Megan Forsyth
Phone:
857-215-1405
Email:
megan_forsyth@dfci.harvard.edu
Investigator:
Last name:
Jennifer Crombie, MD
Email:
Principal Investigator
Start date:
November 15, 2023
Completion date:
June 6, 2031
Lead sponsor:
Agency:
Jennifer Crombie, MD
Agency class:
Other
Collaborator:
Agency:
Merck Sharp & Dohme LLC
Agency class:
Industry
Source:
Dana-Farber Cancer Institute
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT05934448
